ANNX: Annexon Total Debt to Capital

Annexon, Inc. (ANNX) develops drugs to prevent neuronal destruction by blocking the C1q protein, a process protected by patents. The production capacities of external laboratories are certified and operating according to plan. The market trend of the asset shown on this price chart indicates that the total debt-to-equity ratio is 0.14. The business relies on outsourcing clinical trials, allowing the team to remain agile without incurring massive infrastructure costs.

This indicator assesses the degree of business dependence on borrowed funds relative to equity. This financial stability ratio chart visualizes the balance between debt obligations and net assets. An increase in this metric signals higher financial leverage and default risks. For Annexon, Inc. (ANNX), low indebtedness is critically important, as it ensures the necessary access to capital to continue costly neurological research.